Jaa Roberson
Ufficiale delle Risorse Umane presso DAY ONE BIOPHARMACEUTICALS, INC.
Posizioni attive di Jaa Roberson
Società | Posizione | Inizio | Fine |
---|---|---|---|
DAY ONE BIOPHARMACEUTICALS, INC. | Ufficiale delle Risorse Umane | 13/09/2021 | - |
Storia della carriera di Jaa Roberson
Precedenti posizioni note di Jaa Roberson
Società | Posizione | Inizio | Fine |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Ufficiale delle Risorse Umane | 01/05/2018 | 01/11/2020 |
ACHAOGEN | Ufficiale delle Risorse Umane | - | - |
Formazione di Jaa Roberson
Rice University | Undergraduate Degree |
San Francisco Conservatory of Music | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- Jaa Roberson
- Esperienza